Harborside


Claritas Pharmaceuticals, Inc.

CVE: CLAS


Canadian symbol: CLAS.V
US symbol: KALTF

Currency in CAD

Valuation Measures

Market Cap (intraday) 512.74M
Enterprise Value 311.77M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)4.62
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 7N/A

Trading Information

Stock Price History

Beta (5Y Monthly) 2.76
52-Week Change 3-45.00%
S&P500 52-Week Change 334.98%
52 Week High 32.2000
52 Week Low 30.3000
50-Day Moving Average 30.3788
200-Day Moving Average 30.7104

Share Statistics

Avg Vol (3 month) 352.95k
Avg Vol (10 day) 332.04k
Shares Outstanding 535.38M
Implied Shares Outstanding 6N/A
Float 35.31M
% Held by Insiders 10.28%
% Held by Institutions 10.00%
Shares Short (Aug. 30, 2021) 46.29k
Short Ratio (Aug. 30, 2021) 40.1
Short % of Float (Aug. 30, 2021) 4N/A
Short % of Shares Outstanding (Aug. 30, 2021) 40.02%
Shares Short (prior month Jul. 29, 2021) 410.93k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3Jan. 10, 2017
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Currency in USD.

Fiscal Year

Fiscal Year Ends Dec. 30, 2020
Most Recent Quarter (mrq)Jun. 29, 2021

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)0.91%
Return on Equity (ttm)64.43%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA N/A
Net Income Avi to Common (ttm)1.68M
Diluted EPS (ttm)-0.2340
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)282k
Total Cash Per Share (mrq)0.01
Total Debt (mrq)542k
Total Debt/Equity (mrq)19.62
Current Ratio (mrq)1.45
Book Value Per Share (mrq)0.08

Cash Flow Statement

Operating Cash Flow (ttm)-405k
Levered Free Cash Flow (ttm)-11.34M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
CLAS.V
Claritas Pharmaceuticals
4 weeks ago
CLAS.V
Claritas Pharmaceuticals
1 month ago
CLAS.V
Claritas Pharmaceuticals
6 months ago
CLAS.V
Claritas Pharmaceuticals
6 months ago
CLAS.V
Claritas Pharmaceuticals
6 months ago
CLAS.V
Claritas Pharmaceuticals
1 year ago
CLAS.V
Claritas Pharmaceuticals
1 year ago
CLAS.V
Claritas Pharmaceuticals
1 year ago
CLAS.V
Claritas Pharmaceuticals
1 year ago
CLAS.V
Claritas Pharmaceuticals
1 year ago
CLAS.V
Claritas Pharmaceuticals
1 year ago
CLAS.V
Claritas Pharmaceuticals
1 year ago
CLAS.V
Claritas Pharmaceuticals
1 year ago
CLAS.V
Claritas Pharmaceuticals
1 year ago
CLAS.V
Claritas Pharmaceuticals
2 years ago
CLAS.V
Claritas Pharmaceuticals
2 years ago
CLAS.V
Claritas Pharmaceuticals
2 years ago
CLAS.V
Claritas Pharmaceuticals
2 years ago
CLAS.V
Claritas Pharmaceuticals
2 years ago
CLAS.V
Claritas Pharmaceuticals
2 years ago
CLAS.V
Claritas Pharmaceuticals
2 years ago
CLAS.V
Claritas Pharmaceuticals
2 years ago
CLAS.V
Claritas Pharmaceuticals
2 years ago
CLAS.V
Claritas Pharmaceuticals
2 years ago
CLAS.V
Claritas Pharmaceuticals
2 years ago
CLAS.V
Claritas Pharmaceuticals
2 years ago
CLAS.V
Claritas Pharmaceuticals
2 years ago
CLAS.V
Claritas Pharmaceuticals
2 years ago
CLAS.V
Claritas Pharmaceuticals
2 years ago
CLAS.V
Claritas Pharmaceuticals
2 years ago
CLAS.V
Claritas Pharmaceuticals
2 years ago
CLAS.V
Claritas Pharmaceuticals
2 years ago
CLAS.V
Claritas Pharmaceuticals
2 years ago
CLAS.V
Claritas Pharmaceuticals
2 years ago
CLAS.V
Claritas Pharmaceuticals
2 years ago
CLAS.V
Claritas Pharmaceuticals
2 years ago
CLAS.V
Claritas Pharmaceuticals
2 years ago
CLAS.V
Claritas Pharmaceuticals
2 years ago
CLAS.V
Claritas Pharmaceuticals
2 years ago
CLAS.V
Claritas Pharmaceuticals
2 years ago

Analysts data is not available


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
0.28%% of Shares Held by All Insider
0.00%% of Shares Held by Institutions
0.00%% of Float Held by Institutions
0Number of Institutions Holding Shares
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Claritas Pharmaceuticals, Inc.


Claritas Announces Option to Acquire Rights to Novel Drug for Treatment of COVID-19 Related ARDS

Claritas Announces Option to Acquire Rights to Novel Drug for Treatment of COVID-19 Related ARDS

SAN FRANCISCO and TORONTO, Sept. 16, 2021 -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: CLAS.V) (the "Company" or "Claritas") today announced that it has entered into a binding Letter of Intent (the “LOI”) with Biozeus Biopharmaceuticals S. A., a Brazilian corporation (“Biozeus”), under which Biozeus will grant to Claritas... Read More...
Claritas Announces Proposed Financing with Obsidian Global GP, LLC, Receipt of Australian Tax Credit, and Start of Phase 1 Clinical Study of R-107

Claritas Announces Proposed Financing with Obsidian Global GP, LLC, Receipt of Australian Tax Credit, and Start of Phase 1 Clinical Study of R-107

SAN FRANCISCO and TORONTO, Aug. 18, 2021 -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTD) (the "Company" or "Claritas") is pleased to announce that, subject to TSXV approval, it will close the first tranche of a brokered private placement offering (the “Offering”) of convertible debentures with Obsidian Global Partners... Read More...
Claritas Cites Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe COVID-19 Pneumonia as Validation of the Company's Nitric Oxide-Releasing Compound, R-107

Claritas Cites Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe COVID-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107

SAN FRANCISCO and TORONTO, July 26, 2021 -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that a recently published study led by clinicians at Royal Brompton & Harefield NHS Foundation Trust1 validates the potential of the Company’s proprietary nitric oxide releasing co... Read More...
Claritas Announces Additional Data in Validated Animal Model of PAH Demonstrating Ability of R-107 to Prevent, Treat, and Reverse Established Disease

Claritas Announces Additional Data in Validated Animal Model of PAH Demonstrating Ability of R-107 to Prevent, Treat, and Reverse Established Disease

SAN FRANCISCO and TORONTO, July 21, 2021 -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") is pleased to provide additional detail regarding exceptionally positive data with R-107 in a validated animal model of pulmonary arterial hypertension (“PAH”). These data are unprecedented in the sci... Read More...
Claritas Announces Transfer of GVHD Program and Cancellation of Related Debt as Company Focuses on Nitric Oxide Therapeutics

Claritas Announces Transfer of GVHD Program and Cancellation of Related Debt as Company Focuses on Nitric Oxide Therapeutics

SAN FRANCISCO and TORONTO, June 01, 2021 -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that it has entered into an agreement (the “Debt Forgiveness Agreement”) with the former shareholders of Talent Biotechs Ltd. (the “Talent Shareholders”), under which Claritas... Read More...
Kalytera Announces Closing of Private Placement of Common Shares and Common Share Purchase Warrants, and Provides Corporate Update

Kalytera Announces Closing of Private Placement of Common Shares and Common Share Purchase Warrants, and Provides Corporate Update

SAN FRANCISCO, Aug. 07, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today provided the following updates regarding recent and ongoing activities.Private Placement As previously announced on July 24, 2020, the Company closed in escrow it’s previously announced non-brokered private pla... Read More...
Kalytera Announces Escrowed Closing of Private Placement of Common Shares and Common Share Purchase Warrants

Kalytera Announces Escrowed Closing of Private Placement of Common Shares and Common Share Purchase Warrants

SAN FRANCISCO, July 24, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") announced today that on and effective July 22, 2020 it has closed in escrow its previously announced non-brokered private placement (the “Private Placement”) of units comprised of common shares (“Shares”) and one hal... Read More...
Kalytera Announces Exclusive License Agreement with Salzman Group for Development and Commercialization of R-107 for Treatment of Coronavirus and COVID-19 Infection

Kalytera Announces Exclusive License Agreement with Salzman Group for Development and Commercialization of R-107 for Treatment of Coronavirus and COVID-19 Infection

Exclusive License is Part of Larger Transaction to Acquire Salzman GroupSAN FRANCISCO, July 16, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced that it has entered into a License Agreement (the “License Agreement”) with Salzman Group, Inc. (“Salzman Group”), under which S... Read More...
Kalytera Announces Private Placement of Common Shares and Common Share Purchase Warrants

Kalytera Announces Private Placement of Common Shares and Common Share Purchase Warrants

SAN FRANCISCO, July 15, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") announces that it has received conditional approval from the TSX Venture Exchange ("TSXV”) and partial revocation orders from the British Columbia and Ontario Securities Commissions granted today (the “Order”) to com... Read More...
Kalytera Provides Updates Regarding Annual Filings, the Acquisition of Salzman Group, and the Company's Private Placement

Kalytera Provides Updates Regarding Annual Filings, the Acquisition of Salzman Group, and the Company’s Private Placement

SAN FRANCISCO, June 30, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today provided updates regarding the following three matters: (1) the delay in filing of its annual financial statements for the year ending December 31, 2019 and the accompanying Management’s Discussion and Analysis... Read More...
Kalytera Provides Update Regarding Acquisition of Salzman Group

Kalytera Provides Update Regarding Acquisition of Salzman Group

SAN FRANCISCO, June 16, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") announced today that it is working with Salzman Group toward completing definitive agreements for Kalytera’s acquisition of Salzman Group (the “Acquisition”). On May 19, 2020, Kalytera announced that it had signed a ... Read More...
Kalytera Announces Data Demonstrating that R-107 Prevents Tissue Damage and Increases Survival in a Murine Study of Chlorine Inhalational Lung Injury

Kalytera Announces Data Demonstrating that R-107 Prevents Tissue Damage and Increases Survival in a Murine Study of Chlorine Inhalational Lung Injury

SAN FRANCISCO, June 15, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced proof-of-concept data demonstrating that R-107 reduces tissue damage and increases survival in a lethal rodent model of chlorine inhalational lung injury (“CILI”) that mimics the pulmonary damage of c... Read More...
Kalytera Announces Data from Study in Rats Demonstrating Proof of Concept for R-107 in COVID-19 Associated PAH

Kalytera Announces Data from Study in Rats Demonstrating Proof of Concept for R-107 in COVID-19 Associated PAH

SAN FRANCISCO, June 09, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced new proof-of-concept data for R-107, its liquid nitric oxide donor, in treatment of pulmonary arterial hypertension (“PAH”) in the setting of acute respiratory distress syndrome (“ARDS”). These result... Read More...
Kalytera Provides Data Demonstrating that Prodrug R-107 Provides Sustained Release of Nitric Oxide  

Kalytera Provides Data Demonstrating that Prodrug R-107 Provides Sustained Release of Nitric Oxide  

SAN FRANCISCO, June 05, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced new in vivo data demonstrating that R-107 exhibits rapid conversion to its active payload R-100 in rats, followed by sustained release of nitric oxide from R-100.Kalytera announced on May 19, 2020 tha... Read More...
Kalytera Announces Filing of Provisional Patent Protecting Use of R-107 for Treatment of Coronavirus and COVID-19 Associated Pneumonia

Kalytera Announces Filing of Provisional Patent Protecting Use of R-107 for Treatment of Coronavirus and COVID-19 Associated Pneumonia

SAN FRANCISCO, June 02, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced that Salzman Group, Inc. has filed a provisional patent application protecting the use of its proprietary, liquid, nitric oxide donor, R-107, for therapy of coronavirus and COVID-19 associated pneumon... Read More...
Kalytera Announces Data Demonstrating that R-107 Preserves Organ Function in a Murine Study Mimicking COVID-19 Lung Disease

Kalytera Announces Data Demonstrating that R-107 Preserves Organ Function in a Murine Study Mimicking COVID-19 Lung Disease

SAN FRANCISCO, May 29, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced new proof-of-concept data demonstrating that R-107 reduces tissue damage and preserves organ function in a lethal rodent model of sepsis that resembles the circulatory shock seen with COVID-19 associat... Read More...
Kalytera Announces Binding Agreement to Acquire Salzman Group

Kalytera Announces Binding Agreement to Acquire Salzman Group

SAN FRANCISCO, May 19, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") announced today that it has signed a binding Letter of Intent dated May 12, 2020 (the “LOI”) to acquire Salzman Group, Inc., a privately held company located in West Tisbury, MA (“Salzman Group”). Salzman Group is t... Read More...
Kalytera and Stero Biotechs Will Not Proceed with Acquisition

Kalytera and Stero Biotechs Will Not Proceed with Acquisition

SAN FRANCISCO, April 13, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") has announced that it will not proceed with the previously announced acquisition of Stero Biotechs, Ltd. (“Stero”), and that Stero and Kalytera have terminated the Letter of Intent relating to the acquisition.“Alt... Read More...
Kalytera Provides Additional Detail Regarding Terms of Stero Biotechs, Ltd. Acquisition

Kalytera Provides Additional Detail Regarding Terms of Stero Biotechs, Ltd. Acquisition

SAN FRANCISCO and TEL AVIV, Israel, March 18, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today provided additional details regarding the terms of its planned acquisition of Stero Biotechs, Ltd. (“Stero”). Stero is a privately held Israeli company that is developing cannabidiol (“C... Read More...
Kalytera Announces Modification to Sale Period for Shares Issued under Payments Agreement

Kalytera Announces Modification to Sale Period for Shares Issued under Payments Agreement

SAN FRANCISCO, Calif. and TEL AVIV, Israel, Feb. 19, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced a modification to the sale period contemplated by the irrevocable selling agreement between Salzman Group and its broker with respect to common shares of Kalytera.  The ... Read More...
Kalytera Announces New Payments Agreement with the Salzman Group of Israel

Kalytera Announces New Payments Agreement with the Salzman Group of Israel

SAN FRANCISCO and TEL AVIV, Israel, Feb. 07, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has entered into a new agreement reached with the Salzman Group of Israel (the “Agreement”), under which Kalytera will pay the Salzman Group USD$300,000 through issuance... Read More...
Kalytera Announces Intention to Seek Amendment of Secured Convertible Debentures Due December 2019

Kalytera Announces Intention to Seek Amendment of Secured Convertible Debentures Due December 2019

SAN FRANCISCO and TEL AVIV, Israel, Dec. 20, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has not paid the principal (in the amount of C$453,000) and interest (in the amount of C$19,323.96) owing on its 9% secured convertible debentures due December 20, 2019 ... Read More...
Curaleaf Executive Chairman Boris Jordan Named to Bloomberg Businessweek's 2019 Bloomberg 50 List

Curaleaf Executive Chairman Boris Jordan Named to Bloomberg Businessweek's 2019 Bloomberg 50 List

The annual list includes innovators, entrepreneurs, and leaders who have changed the global business landscape in measurable ways over the past yearWAKEFIELD, Mass., Dec. 4, 2019 -- Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf"), a leading vertically integrated cannabis operator in the United States, is proud to announce ... Read More...
Published Studies Provide Further Support For Kalytera’s Program Evaluating CBD in GVHD

Published Studies Provide Further Support For Kalytera’s Program Evaluating CBD in GVHD

SAN FRANCISCO and TEL AVIV, Israel, Nov. 22, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that research reported in two peer-reviewed articles published in Blood provide further evidence supporting the activity of cannabidiol (“CBD”) in prevention and treatment of ac... Read More...
Kalytera Provides Update on Private Placement of Common Shares and Common Share Purchase Warrants

Kalytera Provides Update on Private Placement of Common Shares and Common Share Purchase Warrants

SAN FRANCISCO and TEL AVIV, Israel, Oct. 21, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) is pleased to announce that it has closed an additional tranche of its private placement, for 1,974,445 common shares of the Company and 1,974,445 common share purchase warrants for aggregate g... Read More...
Kalytera Announces Notice of Allowance of EU Patent for Prevention and Treatment of Graft Versus Host Disease

Kalytera Announces Notice of Allowance of EU Patent for Prevention and Treatment of Graft Versus Host Disease

SAN FRANCISCO and TEL AVIV, Israel, Oct. 02, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") is pleased to announce that the European Patent Office has issued a Notice of Allowance for EU Patent Application Number 14791611.8 covering the use of cannabidiol (“CBD”) in the treatment of g... Read More...
Kalytera Announces Closing of First Tranche of Private Placement of Common Shares and Common Share Purchase Warrants

Kalytera Announces Closing of First Tranche of Private Placement of Common Shares and Common Share Purchase Warrants

SAN FRANCISCO and TEL AVIV, Israel, Sept. 16, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the “Company” or “Kalytera”) is pleased to announce the closing of the first tranche of its private placement, for 10,946,423 common shares of the Company and 10,946,423 common share purchase warrants for aggregate gross... Read More...
Kalytera Announces Management-Led Private Placement of Up To $1.5 Million of Common Shares and Common Share Purchase Warrants

Kalytera Announces Management-Led Private Placement of Up To $1.5 Million of Common Shares and Common Share Purchase Warrants

SAN FRANCISCO and TEL AVIV, Israel, Aug. 21, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it intends to raise up to approximately CDN $1.5 million (USD $1.13 million) in a private placement (the “Private Placement”) of common shares and common share purchase war... Read More...
Kalytera to Conclude Phase 2 Clinical Study and Initiate Phase 3 Study

Kalytera to Conclude Phase 2 Clinical Study and Initiate Phase 3 Study

Significantly Positive Phase 2 Results Eliminate Need for High Dose CohortSAN FRANCISCO and TEL AVIV, Israel, Aug. 19, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that interim results from the Company’s Phase 2 clinical study evaluating cannabidiol (“CBD”) for the p... Read More...
Kalytera Will Not Proceed with Vote on Potential Share Consolidation

Kalytera Will Not Proceed with Vote on Potential Share Consolidation

SAN FRANCISCO and TEL AVIV, Israel, July 26, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) announced today that after consultations with major shareholders, the board of directors of the Company has decided not to proceed at this time with the shareholder vote with respect to the aut... Read More...
Kalytera Announces Additional Progress with Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain

Kalytera Announces Additional Progress with Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain

SAN FRANCISCO and TEL AVIV, Israel, June 18, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has invented a novel first-in-class cannabinoid molecule, designated KAL-1816, that strongly and selectively binds with and activates the alpha3 glycine pain receptor.Ac... Read More...
Coming Soon.
SymbolExchangePriceChangeAs of
CLAS.V
TSX Venture Exchange (former Canadian Ventures Exchange)
TSX Venture Exchange (former Canadian Ventures Exchange)0.36CAD+9.23%
S6VA.F
Frankfurt Stock Exchange
Frankfurt Stock Exchange0.20EUR-3.77%
KALTF.PK
US 'Other OTC' and Grey Market
US 'Other OTC' and Grey Market0.28USD+9.58%
KALTF.PQ
OTC MARKETS GROUP L1 AND L2
OTC MARKETS GROUP L1 AND L20.28USD+13.07%

Delayed data (1h)
NameAgePositionAppointed
Robert E. Farrell
Chairman of the Board, President, Chief Executive Officer
69Chairman of the Board, President, Chief Executive Officer2021
Victoria D. Rudman
Interim Chief Financial Officer, Treasurer, Secretary
52Interim Chief Financial Officer, Treasurer, Secretary2018
Salvatore Cuzzocrea
Independent Director
--Independent Director2021
Perenlei Enkhbaatar
Independent Director
--Independent Director2021


Share this page